Novartis India Adjusts Evaluation Amid Mixed Technical Indicators and Valuation Concerns

Jul 04 2025 08:05 AM IST
share
Share Via
Novartis India has recently experienced a change in its evaluation, reflecting a shift in technical trends. The stock's performance metrics indicate a slight decline in price, with a year-over-year return of -4.45%. The company shows strong operating profit growth, but its valuation appears high compared to peers.
Novartis India, a player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects a shift in technical trends, moving from a sideways pattern to a mildly bullish stance. The technical indicators present a mixed picture; while the MACD shows bullish signals on a weekly basis, it leans mildly bearish on a monthly scale. The Relative Strength Index (RSI) indicates bearish conditions weekly, with no significant signals monthly.

The stock's performance metrics reveal a current price of 1051.20, slightly down from the previous close of 1052.10. Over the past year, Novartis India has generated a return of -4.45%, contrasting with a profit increase of 18.4%. The company maintains a low Debt to Equity ratio and has demonstrated robust growth in operating profit, averaging an annual rate of 141.64%.

Despite its small-cap status, domestic mutual funds hold a minimal stake in the company, which may suggest caution regarding its current valuation. The stock trades at a premium compared to its peers, with a Price to Book Value of 3.6, indicating a potentially expensive valuation relative to historical averages.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Why is Novartis India falling/rising?
Dec 05 2025 12:56 AM IST
share
Share Via
Why is Novartis India falling/rising?
Nov 06 2025 10:05 PM IST
share
Share Via
Is Novartis India overvalued or undervalued?
Nov 05 2025 08:06 AM IST
share
Share Via
Is Novartis India overvalued or undervalued?
Nov 03 2025 08:04 AM IST
share
Share Via
Is Novartis India overvalued or undervalued?
Nov 02 2025 08:04 AM IST
share
Share Via
Is Novartis India overvalued or undervalued?
Nov 01 2025 08:05 AM IST
share
Share Via